Partner Therapeutics, Inc. (PTx), a private, fully-integrated biotechnology company announced today that the New England Journal ...
The publication reviews the results of 204 patients with 12 tumor types enrolled and treated on the eNRGy study, concluding “Zenocutuzumab demonstrated durable efficacy in patients with advanced NRG1+ ...
The PATHWAY HER2 (4B5) test is now FDA-approved to assess HER2-ultralow status in metastatic breast cancer, expanding its ...
Senti Bio aims to improve cancer therapeutics with customizable gene circuits, or multi-gene constructs capable of ...
Earlier today, Munich Re published the latest chapter in its Life Science Report series, delving into ‘Improving Cancer ...
During a Case-Based Roundtable event, Laura Huppert, MD, discussed data and considerations around using T-DXd in breast ...
During 2024, the radiopharmaceutical Pluvicto achieved blockbuster status, while sales of the breast cancer drug Kisqali grew 46 percent compared to 2023.
The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...
Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF ...
AstraZeneca and Daiichi Sankyo have claimed their seventh FDA approval for Enhertu, getting the go-ahead for the blockbuster ...
A new statistical tool that combines multiple clinical and pathologic factors with a patient's 21-gene Oncotype DX Breast ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback